Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + antiangiogenic agents + TACE as neoadjuvant therapy for borderline resectable hepatocellular carcinoma
ChiCTR2100043462Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC) and liver cancer, sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Major pathological response. Started Apr 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on ChiCTR2100043462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043462.